Some preclinical studies showed the potential interest of noninvasive SPECT or PET imaging of tumor PD-L1 expression using radiolabelled anti-PD-L1 antibodies [74,75,76]; yet, to our knowledge and according to Clinicaltrials.gov, only one clinical study is under recruitment. This evidence concerns the gene CD274 and neoplasm.